Citations

Clear

6273 citation(s) found for "To, Andrew".

Cost-effectiveness of posterior lumbar interbody fusion and/or transforaminal lumbar interbody fusion for grade 1 lumbar spondylolisthesis: a 5-year Quality Outcomes Database study
Yee, Timothy J., Liles, Campbell, Johnson, Sarah E. , DiGiorgio, Anthony M. , Alan, Nima , Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Knightly, John J. , Fu, Kai-Ming, Foley, Kevin T. , Shaffrey, Mark E., Bydon, Mohamad , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Shaffrey, Christopher I. , Slotkin, Jonathan R., Wang, Michael Y. , Haid, Regis W., Glassman, Steven D. , Virk, Michael S., Mummaneni, Praveen V., Ambati, Vardhaan , Asher, Anthony L., Virk, Michael S., Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | August 17, 2024 | Volume: 41 | Issue: 5 | Pages: 596-603

10.3171/2024.5.spine24112 | PMID 39151203 Get It

OBJECTIVE Posterior lumbar interbody fusion (PLIF) and/or transforaminal lumbar interbody fusion (TLIF), referred to as "PLIF/TLIF," is a commonly performed operation for lumbar spondylolisthesis. Its long-term cost-effectiveness has not been well described. The aim of this study was to determine the 5-year cost-effectiveness of PLIF/TLIF for grade 1 degenerative lumbar spondylolisthesis using prospective data collected from the multicenter Quality Outcomes Database (QOD). METHODS Patients enrolled in the prospective, multicenter QOD grade 1 lumbar spondylolisthesis module were included if they underwent single-stage PLIF/TLIF. EQ-5D scores at baseline, 3 months, 12 months, 24 months, 36 months, and 60 months were used to calculate gains in quality-adjusted life years (QALYs) associated with surgery relative to preoperative baseline. Healthcare-related costs associated with the index surgery and related reoperations were calculated using Medicare reimbursement–based cost estimates and validated using price transparency diagnosis-related group (DRG) charges and Medicare charge-to-cost ratios (CCRs). Cost per QALY gained over 60 months postoperatively was assessed. RESULTS Across 12 surgical centers, 385 patients were identified. The mean patient age was 60.2 (95% CI 59.1–61.3) years, and 38% of patients were male. The reoperation rate was 5.7%. DRG 460 cost estimates were stable between our Medicare reimbursement–based models and the CCR-based model, validating the focus on Medicare reimbursement. Across the entire cohort, the mean QALY gain at 60 months postoperatively was 1.07 (95% CI 0.97–1.18), and the mean cost of PLIF/TLIF was $31,634. PLIF/TLIF was associated with a mean 60-month cost per QALY gained of $29,511. Among patients who did not undergo reoperation (n = 363), the mean 60-month QALY gain was 1.10 (95% CI 0.99–1.20), and cost per QALY gained was $27,591. Among those who underwent reoperation (n = 22), the mean 60-month QALY gain was 0.68 (95% CI 0.21–1.15), and the cost per QALY gained was $80,580. CONCLUSIONS PLIF/TLIF for degenerative grade 1 lumbar spondylolisthesis was associated with a mean 60-month cost per QALY gained of $29,511 with Medicare fees. This is far below the well-established societal willingness-to-pay threshold of $100,000, suggesting long-term cost-effectiveness. PLIF/TLIF remains cost-effective for patients who undergo reoperation.
Predictors of patient satisfaction in the surgical treatment of cervical spondylotic myelopathy
Schüpper, Alexander J. , DiDomenico, Joseph D., Johnson, Sarah E. , Bisson, Erica F. , Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Shaffrey, Christopher I., Gottfried, Oren N., Park, Christine , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Chan, Andrew K. , Tumialán, Luis M. , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V., Uribe, Juan S. , Turner, Jay D. , Farber, Samuel Harrison , Fu, Kai-Ming, Shaffrey, Christopher I. , Park, Paul , Mummaneni, Praveen V. , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | August 17, 2024 | Volume: 41 | Issue: 5 | Pages: 611-618

10.3171/2024.5.spine24326 | PMID 39151188 Get It

OBJECTIVE Patients with cervical spondylotic myelopathy (CSM) experience progressive neurological impairment. Surgical intervention is often pursued to halt neurological symptom progression and allow for recovery of function. In this paper, the authors explore predictors of patient satisfaction following surgical intervention for CSM. METHODS This is a retrospective review of prospectively collected data from the multicenter Quality Outcomes Database. Patients who underwent surgical intervention for CSM with a minimum follow-up of 2 years were included. Patient-reported satisfaction was defined as a North American Spine Society (NASS) satisfaction score of 1 or 2. Patient demographics, surgical parameters, and outcomes were assessed as related to patient satisfaction. Patient quality of life scores were measured at baseline and 24-month time points. Univariate regression analyses were performed using the chi-square test or Student t-test to assess patient satisfaction measures. Multivariate logistic regression analysis was conducted to assess for factors predictive of postoperative satisfaction at 24 months. RESULTS A total of 1140 patients at 14 institutions with CSM who underwent surgical intervention were included, and 944 completed a patient satisfaction survey at 24 months postoperatively. The baseline modified Japanese Orthopaedic Association (mJOA) score was 12.0 ± 2.8. A total of 793 (84.0%) patients reported satisfaction (NASS score 1 or 2) after 2 years. Male and female patients reported similar satisfaction rates (female sex: 47.0% not satisfied vs 48.5% satisfied, p = 0.73). Black race was associated with less satisfaction (26.5% not satisfied vs 13.2% satisfied, p < 0.01). Baseline psychiatric comorbidities, obesity, and length of stay did not correlate with 24-month satisfaction. Crossing the cervicothoracic junction did not affect satisfactory scores (p = 0.19), and minimally invasive approaches were not associated with increased patient satisfaction (p = 0.14). Lower baseline numeric rating scale neck pain scores (5.03 vs 5.61, p = 0.04) and higher baseline mJOA scores (12.28 vs 11.66, p = 0.01) were associated with higher satisfaction rates. CONCLUSIONS Surgical treatment of CSM results in a high rate of patient satisfaction (84.0%) at the 2-year follow-up. Patients with milder myelopathy report higher satisfaction rates, suggesting that intervention earlier in the disease process may result in greater long-term satisfaction.
The emerging field of viroimmunotherapy for pediatric brain tumors
García-Moure, Marc , Laspidea, Virginia , Gupta, Sumit , Khatua, Soumen , Parthasarathy, Akhila , Lang, Frederick F. , Fueyo, Juàn , Gomez‐Manzano, Candelaria , Fueyo, Juan , Gomez-Manzano, Candelaria , Gillard, Andrew Gregg , He, Jiasen , Alonso, Marta M

Mayo Clinic

Neuro-Oncology | August 16, 2024 | Volume: 26 | Issue: 11 | Pages: 1981-1993

10.1093/neuonc/noae160 | PMID 39148489 Get It

Abstract Pediatric brain tumors are the most common solid tumors in children. Even to date, with the advances in multimodality therapeutic management, survival outcomes remain dismal in some types of tumors, such as pediatric-type diffuse high-grade gliomas or central nervous system embryonal tumors. Failure to understand the complex molecular heterogeneity and the elusive tumor and microenvironment interplay continues to undermine therapeutic efficacy. Developing a strategy that would improve survival for these fatal tumors remains unmet in pediatric neuro-oncology. Oncolytic viruses (OVs) are emerging as a feasible, safe, and promising therapy for brain tumors. The new paradigm in virotherapy implies that the direct cytopathic effect is followed, under certain circumstances, by an antitumor immune response responsible for the partial or complete debulking of the tumor mass. OVs alone or combined with other therapeutic modalities have been primarily used in adult neuro-oncology. A surge in encouraging preclinical studies in pediatric brain tumor models recently led to the clinical translation of OVs with encouraging results in these tumors. In this review, we summarize the different virotherapy tested in preclinical and clinical studies in pediatric brain tumors, and we discuss the limitations and future avenues necessary to improve the response of these tumors to this type of therapy.
Clinical presentation and factors associated with gluten exposure in children with celiac disease
Krueger, Andrew , Fahey, Lisa M. , Sun, Qin , Regis, Stephanie , Khavari, Nasim, Jericho, Hilary , Badalyan, Vahe , Absah, Imad , Leonard, Maureen M. , Weisbrod, Vanessa , Hajjat, Temara , Shull, Mary , Silvester, Jocelyn A. , Mallon, Daniel , RAISE‐CD, Silvester, Jocelyn A , Mallon, Daniel , Regis, Stephanie , Weisbrod, Vanessa , Krueger, Andrew, Verma, Ritu , Lee, Dale Young , RAISE‐CD

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | August 16, 2024 | Volume: 79 | Issue: 4 | Pages: 895-904

10.1002/jpn3.12321 | PMID 39149789 Get It

AbstractObjectivesThe prevalence of celiac disease (CeD) is increasing, yet it is still underdiagnosed, in part because of its heterogeneous presentation. Diagnostic criteria are evolving and management with strict adherence to a gluten‐free diet is challenging for many. We aimed to characterize the clinical presentation of CeD among a large multicenter cohort of pediatric patients and to identify factors associated with gluten‐free diet adherence.MethodsPatients with CeD aged 0–18 years were recruited from 11 United States health centers. Parents completed surveys about gluten‐free diet adherence and patient electronic health records were reviewed. Logistic regression analyses were performed to identify risk factors associated with gluten exposure.ResultsCharts were reviewed for 460 children with a median age of 6.4 years. Abdominal pain was reported in 57% of the cohort, but diverse symptoms were identified. Parent surveys were completed for 455 participants. Sixty‐five (14%) participants were at high risk for gluten exposure based on parental reports of weekly or daily gluten exposure or eating gluten by choice in the past year. Participants under the age of 5 years had a lower risk of gluten exposure, while participants without repeat serology testing 18 months after initial diagnosis were at higher risk of gluten exposure.ConclusionsIn a large, multicenter cohort of pediatric CeD patients, clinical presentation is highly variable, necessitating a high index of suspicion to make a diagnosis. Parent surveys indicate that 14% of patients are at high risk of gluten exposure, with patient age and lack of close follow‐up associated with gluten‐free diet adherence.
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Acharya, Sahaja , Allison, Jenna , Alva, Elizabeth, Arndt, Carola, Benedetti, Daniel J. , Church, Alanna J. , Davidoff, Andrew M. , Desai, Ami V. , DuBois, Steven G. , Fair, Douglas , Farinhas, Joaquim M. , Harrison, Douglas J. , Huang, Frederick S., Iskander, Paul, Kreissman, Susan G. , Macy, Margaret E. , Pashankar, Farzana , Pendyala, Praveen, Polites, Stephanie F. , Rabah, Raja , Shimada, Hiroyuki , Slatnick, Leonora R. , Sokol, Elizabeth , Twist, Clare J. , Vo, Kieuhoa T. , Watt, Tanya , Wolden, Suzanne, Zage, Peter E. , Schonfeld, Ryan, Hang, Lisa, Polites, Stephanie, Bagatell, Rochelle , Park, Julie R. , Aldrink, Jennifer H. , Brown, Erin G. , Cho, Steve K. , Na, Brian , Pinto, Navin

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 16, 2024 | Volume: 22 | Issue: 6 | Pages: 413-433

10.6004/jnccn.2024.0040 | PMID 39151455 Get It

Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of the NCCN Guidelines for Neuroblastoma provides recommendations for the diagnosis, risk classification, and treatment of neuroblastoma. The information in these guidelines was developed by the NCCN Neuroblastoma Panel, a multidisciplinary group of representatives with expertise in neuroblastoma, consisting of pediatric oncologists, radiologists, pathologists, surgeons, and radiation oncologists from NCCN Member Institutions. The evidence-based and consensus recommendations contained in the NCCN Guidelines are intended to guide clinicians in selecting the most appropriate treatments for their patients with this clinically heterogeneous disease.
The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group
Pradhan, Amynah , Brin, Mitchell F. , Rosen, Howard J. , Lalvani, Nim, Ashina, Messoud , Phu, Thien , Digre, Kathleen B. , Russo, Andrew F. , Buse, Dawn C. , Tassorelli, Cristina, Goadsby, Peter J., Robertson, Carrie E. , Ezzati, Ali , Pradhan, Amynah A , Charles, Andrew , Ashina, Messoud , Gelfand, Amy A , Dodick, David W , Lipton, R.B. , Robertson, Carrie E , Schwedt, Todd J. , Oshinsky, Michael L. , Charles, Andrew , Burstein, Rami , Gelfand, Amy A. , Dodick, David W. , Pozo‐Rosich, Patricia , Lipton, Richard B. , Ailani, Jessica , Szperka, Christina L. , Charleston, Larry , Powers, Scott W. , Tassorelli, Cristina

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 16, 2024 | Volume: 64 | Issue: 8 | Pages: 912-930

10.1111/head.14797 | PMID 39149968 Get It

Abstract Objective To identify and disseminate research priorities for the headache field that should be areas of research focus during the next 10 years. Background Establishing research priorities helps focus and synergize the work of headache investigators, allowing them to reach the most important research goals more efficiently and completely. Methods The Headache Research Priorities organizing and executive committees and working group chairs led a multistakeholder and international group of experts to develop headache research priorities. The research priorities were developed and reviewed by clinicians, scientists, people with headache, representatives from headache organizations, health‐care industry representatives, and the public. Priorities were revised and finalized after receiving feedback from members of the research priorities working groups and after a public comment period. Results Twenty‐five research priorities across eight categories were identified: human models, animal models, pathophysiology, diagnosis and management, treatment, inequities and disparities, research workforce development, and quality of life. The priorities address research models and methods, development and optimization of outcome measures and endpoints, pain and non‐pain symptoms of primary and secondary headaches, investigations into mechanisms underlying headache attacks and chronification of headache disorders, treatment optimization, research workforce recruitment, development, expansion, and support, and inequities and disparities in the headache field. The priorities are focused enough that they help to guide headache research and broad enough that they are widely applicable to multiple headache types and various research methods. Conclusions These research priorities serve as guidance for headache investigators when planning their research studies and as benchmarks by which the headache field can measure its progress over time. These priorities will need updating as research goals are met and new priorities arise.
Paper 32: Leg Length Changes Following Distal Femoral Osteotomy: Validation of a Predictive Tool and Comparison of Lateral Opening Wedge and Medial Closing Wedge Techniques
Elias, Tristan J. , Brusalis, Christopher M. , Kogan, Monica , Yanke, Adam B. , Haneberg, Erik , Phillips, Andrew , Forlenza, Enrico M. , Wang, Allen S. , Krych, Aaron J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | August 15, 2024 | Volume: 12 | Issue: 7_suppl2 | Pages: No page available

10.1177/2325967124s00044 Get It

Objectives: A DFO can be performed via two techniques: a lateral opening wedge (LOW) osteotomy and a medial closing wedge (MCW) osteotomy. Small case series have looked at how leg length is affected by a lateral opening wedge DFO, however, there is a lack of research comparing these leg length changes to medial closing DFO. Additionally, no studies have presented a model for predicting the leg length changes that will occur following DFO of either technique. Given that limb length differences can lead to accelerated osteoarthritis, back pain, hip pain, and other issues, being able to predict which technique can help prevent this pathology without a secondary procedure would be an important finding. Finally, the medial closing wedge osteotomy can allow for immediate weight-bearing while the lateral opening wedge does not and typically has associated cost with bone grafting. Therefore, we designed this study to validate a tool designed to predict leg length changes after distal femoral osteotomy (DFO) and compare changes following medial closing wedge (MCW) and lateral opening wedge (LOW) techniques. Methods: A collaborative retrospective review was performed of patients from Rush and Mayo Clinic databases who received a DFO and had full-length standing radiographs both pre-and postoperatively. For each preoperative radiograph, the region on the medial (for LOW) or lateral (for MCW) distal femur cortex that would be the “hinge point” during DFO was identified. The distances from the center of the femoral head to the hinge point (“A”), from the hinge point to the center of the tibial plafond (“B”), and the resultant angle at the hinge point (“α”) were measured (Figure 1). Figure 2 demonstrates the equation used to plot a graph of the predicted leg length changes corresponding to the change in α angle produced by DFO. Final leg length was calculated on postoperative radiographs, and the difference between predicted and true leg length changes was compared using paired Wilcoxon signed rank exact tests. Results: 10 MCW and 10 LOW patients were included. For both LOW (n=10) and MCW (n=10) osteotomies, the predicted leg length change was equivalent to the true change measured on postoperative radiographs (LOW P=0.16; MCW P=0.85). LOW DFO’s had 5.10 ± 2.77 mm (range: 1.45-10.87 mm) of leg lengthening, compared to 2.61 ± 1.25 mm (range: 0.50-4.56 mm) of leg shortening (p<0.001) for MCW (Figure 3). On average, there was 0.85 mm of lengthening (range 0.5-1.3 mm) for every 1° of mechanical axis correction with LOW DFO, compared to 0.45 mm of shortening (range: 0.1-1.4 mm) per 1° of MCW correction. Conclusions: This study presents a tool to accurately and reliably predict the leg length changes seen after both medial closing and lateral opening wedge DFO’s. Knowing what leg length changes to expect with each DFO technique is a useful tool that surgeons can utilize during surgical planning. Preoperative radiographic imaging can be used to predict leg length change following DFO with high reliability and accuracy. Surgeons can expect approximately 0.85mm of lengthening per 1° of DFO correction when performing LOW, compared to 0.45mm of shortening per 1° correction for MCW osteotomies.
Methotrexate and Rituximab Use in Highly Recurrent Idiopathic Subglottic Stenosis
Awadallah, Andrew S. , Bowen, Andrew J. , Ali, Hawa M. , O’Byrne, Thomas J., Padilla, Hannah, Khalil, Yousuf H. , Aden, Aisha A. , Edell, Eric S. , Bayan, Semirra L. , Ekbom, Dale C. , Padilla, Hannah M , Bowen, Andrew Jay , Awadallah, Andrew , Bayan, Semirra , Koster, Matthew J.

Mayo Clinic

The Laryngoscope | August 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.31686 | PMID 39140225 Get It

ObjectiveTo evaluate the impact of methotrexate and rituximab therapy on highly recurrent idiopathic subglottic stenosis (iSGS) patients with a negative antineutrophil cytoplasmic antibody titer cANCA(−).MethodsThis was a retrospective cohort study of highly recurrent iSGS patients who recurred within 1 year or less and were treated with methotrexate (MTX), and rituximab (RTX), or a combination of both at different time points (MTX/RTX). Average surgical durations before and after drug treatment were summarized, and the differences were calculated.ResultsA total of 21 female patients with median age of 62 years were included. Fifteen patients were treated with MTX, three were treated with RTX, and five treated with both. Patients treated with immunosuppressants showed a trend toward longer intervals between operations (mean pre‐drug interval: 338; mean post‐drug interval: 697 days) (p‐value = 0.25). Three patients did not recur following drug initiation with median follow‐up of 1265 days. All three treatment groups demonstrated a trend toward increased post‐drug recurrence intervals (MTX: 444 days, RTX: 374 days, MTX/RTX: 55 days), that was not statistically significant. Patients with prior dilations demonstrated longer post‐drug recurrence intervals (mean pre‐drug interval: 341 days, mean post‐drug interval 978 days) (p‐value = 0.17). Four patients in the cohort with the highest recurring disease improved from mean 129 days between operations to 509 days with drug therapy. The most common drug side effect was nausea (16%).ConclusionMTX and RTX may be treatment options for some highly recurrent iSGS patients. Initial results are variable and demonstrate a need for further research on drug candidacy.Level of Evidence3 Laryngoscope, 2024
Validation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett Esophagus
Laun, Sarah , Kann, Lisa , Braun, Jerome J., Gilbert, Stacey, Lunz, Daniel, Pierre, Francia , Kalra, Andrew , Tsai, Hua‐Ling , Wang, Hao , Cheng, Yulan , Ahmed, Yousra , Wang, Kenneth K, Leggett, Cadman L. , Cellini, Ashley, Ioffe, Olga B. , Omstead, Ashten N., Jobe, Blair A. , Korman, Louis Y. , Cornish, Drew, Zellenrath, Pauline A. , Perpetua, Lorrie A., Greenwald, Bruce D. , Maddala, Tara, Meltzer, Stephen J. , Tsai, Hua-Ling , Wang, Hao , Ahmed, Yousra , Leggett, Cadman L , Ioffe, Olga B , Zaidi, Ali Hussainy , Cornish, Drew , Zellenrath, Pauline , Spaander, Manon , Kuipers, Ernst , Greenwald, Bruce D , Meltzer, Stephen J , Braun, Jerome, Ma, Ke , Jit, Simran, Kuipers, Ernst J.

Mayo Clinic

American Journal of Gastroenterology | August 14, 2024 | Volume: 120 | Issue: 6 | Pages: 1296-1306

10.14309/ajg.0000000000003030 | PMID 39140473 Get It

INTRODUCTION: Esophageal adenocarcinoma (EAC) is the second-most lethal cancer in the United States, with Barrett esophagus (BE) being the strongest risk factor. Assessing the future risk of neoplastic progression in patients with BE is difficult; however, high-grade dysplasia (HGD) and early EAC are treatable by endoscopic eradication therapy (EET), with survival rates of 90%. Thus, it would be beneficial to develop a molecular assay to identify high-risk patients, who merit more frequent endoscopic surveillance or EET, as well as low-risk patients, who can avoid EET and undergo less frequent surveillance. METHODS: Deidentified endoscopic biopsies were acquired from 240 patients with BE at 6 centers and confirmed as future progressors or nonprogressors. Tissues were analyzed by a set of methylation-specific biomarker assays. Test performance was assessed in an independent validation set using 4 stratification levels: low risks, low-moderate risks, high-moderate risks, and high risks. RESULTS: Relative to patients in the low-risk group, high-risk patients were 15.2 times more likely to progress within 5 years to HGD or EAC. For patients in the high-risk category, the average risk of progressing to HGD or EAC within 5 years was 21.5%, 4-fold the BE population prevalence within 5 years, whereas low-risk patients had a progression risk of only 1.85%. DISCUSSION: This clinical assay, Esopredict, stratifies future neoplastic progression risk to identify higher-risk patients with BE who can benefit from EET or more frequent surveillance and lower-risk patients who can benefit from reduced surveillance.
Impact of duration of dual anti-platelet therapy on risk of complications after stent-assisted coiling of unruptured aneurysms
Ringer, Andrew J. , Hanel, Ricardó A. , Baig, Ammad A. , Siddiqui, Adnan H. , Lopes, Demetrius K. , Barros, Guilherme , Bass, David I. , Levitt, Michael R. , Young, Christopher C. , Naylor, Ryan M. , Crowley, R. Webster , Serrone, Joseph C. , Kan, Peter , Binning, Mandy J., Veznedaroglu, Erol, Boulos, Alan S. , Lopes, Demetrius Klee , Kan, Peter , Tawk, Rabih G , Levitt, Michael R , Siddiqui, Adnan H , Hanel, Ricardo A , Lanzino, Giuseppe , Tawk, Rabih G.

Mayo Clinic

Journal of NeuroInterventional Surgery | August 13, 2024 | Volume: 17 | Issue: 9 | Pages: 956-960

10.1136/jnis-2024-021977 | PMID 39137967 Get It

Background The optimal duration for dual antiplatelet therapy (DAPT) after stent-assisted coiling (SAC) of intracranial aneurysms is unclear. Longer-term therapy may reduce thrombotic complications but increase the risk of bleeding complications. Methods A retrospective review of prospectively maintained data at 12 institutions was conducted on patients with unruptured intracranial aneurysms who underwent SAC between January 1, 2016 and December 31, 2020, and were followed ≥6 months postprocedure. The type and duration of DAPT, stent(s) used, outcome, length of follow-up, complication rates, and incidence of significant in-stent stenosis (ISS) were collected. Results Of 556 patients reviewed, 450 met all inclusion criteria. Nine patients treated with DAPT <29 days after SAC and 11 treated for 43–89 days were excluded from the final analysis as none completed their prescribed duration of treatment. Eighty patients received short-term DAPT. There were no significant differences in the rate of thrombotic complications during predefined periods of risk in the short, medium, or long-term treatment groups (1/80, 1.3%; 2/188, 1.1%; and 0/162, 0%, respectively). Similarly, no differences were found in the rate of hemorrhagic complications during period of risk in any group (0/80, 0%; 3/188, 1.6%; and 1/162, 0.6%, respectively). Longer duration DAPT did not reduce ISS risk in any group. Conclusions Continuing DAPT >42 days after SAC did not reduce the risk of thrombotic complications or in-stent stenosis, although the risk of additional hemorrhagic complications remained low. It may be reasonable to discontinue DAPT after 42 days following non-flow diverting SAC of unruptured intracranial aneurysms.